The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis - a 30-month prospective, observational cohort study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F21%3A43922214" target="_blank" >RIV/00216208:11120/21:43922214 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/62156489:43110/21:43920303 RIV/00216208:11110/21:10431936 RIV/00064211:_____/21:W0000007 RIV/00216208:11130/21:10431936

Výsledek na webu

<a href="https://doi.org/10.1111/ijcp.14915" target="_blank" >https://doi.org/10.1111/ijcp.14915</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/ijcp.14915" target="_blank" >10.1111/ijcp.14915</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis - a 30-month prospective, observational cohort study

Popis výsledku v původním jazyce

BACKGROUND: Although biologic agents are very effective, solid data proving they are safer than other therapies in psoriasis are still lacking. METHODS: A total of 289 psoriatic patients were followed for 30 months; of which number 118 were treated with topical agents alone, 112 received biologic agents, and the remaining 59 patients were on non-biologic systemic agents. The rates of adverse events in these groups were recorded and statistically analyzed. RESULTS: Patients treated with biologic agents had higher rates of adverse events (p=0.017), including overall infections (p=0.003), respiratory infections (p&lt;0.001), renal, urinary (p&lt;0.001), musculoskeletal, connective tissue (p&lt;0.001, and p=0.021) and oral cavity-related (p=0.046) disorders. Except for the incidence of infections, all the above adverse events occurred more often in our study than in clinical trials. The occurrence of serious adverse events was p=0.066, with the incidence of serious infections being p=0.164. Unlike patients on topical therapy and non-biologic systemic agents, patients treated with biologic agents were forced to discontinue their therapies (p=0.001). The Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) scores were the lowest among patients on biologic agents. CONCLUSION: While biologic agents were the most effective therapies, they were associated with higher rates of treatment discontinuation and adverse events in comparison with other forms of therapy.

Název v anglickém jazyce

The safety profile of biologic agents in comparison with non-biologic systemic agents, and topical compounds in the management of psoriasis - a 30-month prospective, observational cohort study

Popis výsledku anglicky

BACKGROUND: Although biologic agents are very effective, solid data proving they are safer than other therapies in psoriasis are still lacking. METHODS: A total of 289 psoriatic patients were followed for 30 months; of which number 118 were treated with topical agents alone, 112 received biologic agents, and the remaining 59 patients were on non-biologic systemic agents. The rates of adverse events in these groups were recorded and statistically analyzed. RESULTS: Patients treated with biologic agents had higher rates of adverse events (p=0.017), including overall infections (p=0.003), respiratory infections (p&lt;0.001), renal, urinary (p&lt;0.001), musculoskeletal, connective tissue (p&lt;0.001, and p=0.021) and oral cavity-related (p=0.046) disorders. Except for the incidence of infections, all the above adverse events occurred more often in our study than in clinical trials. The occurrence of serious adverse events was p=0.066, with the incidence of serious infections being p=0.164. Unlike patients on topical therapy and non-biologic systemic agents, patients treated with biologic agents were forced to discontinue their therapies (p=0.001). The Psoriasis Area Severity Index (PASI) and Body Surface Area (BSA) scores were the lowest among patients on biologic agents. CONCLUSION: While biologic agents were the most effective therapies, they were associated with higher rates of treatment discontinuation and adverse events in comparison with other forms of therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30216 - Dermatology and venereal diseases

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

International Journal of Clinical Practice

ISSN

1368-5031

e-ISSN

—

Svazek periodika

75

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

"e14915"

Kód UT WoS článku

000703754200001

EID výsledku v databázi Scopus

2-s2.0-85116488777